3,791 Shares in Cencora, Inc. (NYSE:COR) Acquired by Brookwood Investment Group LLC

Brookwood Investment Group LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,791 shares of the company's stock, valued at approximately $1,054,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Net Worth Advisory Group raised its holdings in Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after purchasing an additional 36 shares during the period. Obermeyer Wealth Partners lifted its position in shares of Cencora by 1.3% in the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock valued at $758,000 after acquiring an additional 36 shares in the last quarter. Cromwell Holdings LLC lifted its position in shares of Cencora by 9.5% in the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock valued at $125,000 after acquiring an additional 39 shares in the last quarter. Private Trust Co. NA grew its position in shares of Cencora by 2.5% during the first quarter. Private Trust Co. NA now owns 1,933 shares of the company's stock worth $538,000 after purchasing an additional 47 shares in the last quarter. Finally, Permanent Capital Management LP grew its position in shares of Cencora by 4.0% during the first quarter. Permanent Capital Management LP now owns 1,238 shares of the company's stock worth $344,000 after purchasing an additional 48 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 4,968 shares of the firm's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $294.11, for a total value of $1,461,138.48. Following the transaction, the chief executive officer owned 42,351 shares of the company's stock, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares in the company, valued at $91,271,982.06. This trade represents a 4.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,125 shares of company stock worth $9,993,789. 10.80% of the stock is currently owned by insiders.

Cencora Stock Down 1.5%

Shares of COR stock traded down $4.38 on Monday, reaching $285.98. 997,899 shares of the stock were exchanged, compared to its average volume of 1,587,393. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a market capitalization of $55.43 billion, a price-to-earnings ratio of 33.18, a PEG ratio of 1.44 and a beta of 0.57. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The business's 50 day moving average price is $293.31 and its 200 day moving average price is $274.79.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period in the previous year, the business posted $3.80 earnings per share. The business's revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.

Wall Street Analyst Weigh In

COR has been the subject of several research analyst reports. Citigroup increased their target price on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America increased their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Robert W. Baird increased their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Finally, UBS Group boosted their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $309.83.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.